291 related articles for article (PubMed ID: 31788992)
21. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
23. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Yang C; Feng W; Wu D
J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
[TBL] [Abstract][Full Text] [Related]
24. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
25. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.
Gou M; Si H; Zhang Y; Qian N; Wang Z; Shi W; Dai G
Sci Rep; 2018 Mar; 8(1):4602. PubMed ID: 29545575
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
28. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
[TBL] [Abstract][Full Text] [Related]
30. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
31. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
Leng J; Li DR; Huang LM; Ji XH; Wang DL
Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
[TBL] [Abstract][Full Text] [Related]
32. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
33. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
34. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
35. A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix.
Chen C; Qin S; Li Z; Luo X; Zhang Y; Zhang J; Liu X
Onco Targets Ther; 2019; 12():5805-5811. PubMed ID: 31410025
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
37. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
38. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.
Wang Z; Huang Y; Long L; Zhou L; Huang Y; Gan L; Pu A; Li S; Xie R
J Ovarian Res; 2021 Jul; 14(1):91. PubMed ID: 34247630
[TBL] [Abstract][Full Text] [Related]
39. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
40. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
